Quarterly report pursuant to Section 13 or 15(d)

Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements - Revenue Recognition (Details)

v3.8.0.1
Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements - Revenue Recognition (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Jan. 01, 2018
Dec. 31, 2017
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue $ 7,667 $ 6,966    
CURRENT LIABILITIES        
Deferred revenue 1,751     $ 516
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 992     429
STOCKHOLDERS’ EQUITY        
Accumulated (deficit) (141,799)     $ (134,834)
Biopharma Services        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue 3,658 3,719    
CURRENT LIABILITIES        
Deferred revenue 1,625      
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 516      
Clinical Services        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue 2,342 2,954    
CURRENT LIABILITIES        
Deferred revenue 0      
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 0      
Discovery Services        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue 1,667 $ 293    
CURRENT LIABILITIES        
Deferred revenue 126      
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 476      
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue (836)      
CURRENT LIABILITIES        
Deferred revenue (1,673)      
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 0      
STOCKHOLDERS’ EQUITY        
Accumulated (deficit) 1,673   $ (2,500)  
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09 | Biopharma Services        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue (307)      
CURRENT LIABILITIES        
Deferred revenue (1,547)   1,900  
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 0      
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09 | Clinical Services        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue 0      
CURRENT LIABILITIES        
Deferred revenue 0      
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 0      
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09 | Discovery Services        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue (529)      
CURRENT LIABILITIES        
Deferred revenue (126)   $ 600  
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 0      
Calculated under Revenue Guidance in Effect before Topic 606        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue 6,831      
CURRENT LIABILITIES        
Deferred revenue 78      
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 992      
STOCKHOLDERS’ EQUITY        
Accumulated (deficit) (140,126)      
Calculated under Revenue Guidance in Effect before Topic 606 | Biopharma Services        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue 3,351      
CURRENT LIABILITIES        
Deferred revenue 78      
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 516      
Calculated under Revenue Guidance in Effect before Topic 606 | Clinical Services        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue 2,342      
CURRENT LIABILITIES        
Deferred revenue 0      
NON-CURRENT LIABILITIES        
Deferred revenue, long-term 0      
Calculated under Revenue Guidance in Effect before Topic 606 | Discovery Services        
Consolidated Statements of Operations and Other Comprehensive Loss        
Revenue 1,138      
CURRENT LIABILITIES        
Deferred revenue 0      
NON-CURRENT LIABILITIES        
Deferred revenue, long-term $ 476